|Articles|March 9, 2020

Novotech Wins Contract for Komipharm Coronavirus Covid-19 Trial in South Korea

Asia-Pacific biotech CRO Novotech has been selected for the Komipharm International clinical trial of Panaphix as a potential treatment for coronavirus - Covid-19. Panaphix is a cytokine storm inhibitor that restrains the overproduction of immune cells and their activating compounds, cytokines.

For more information, click here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Articles

ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research
September 15th 2025
Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome
September 15th 2025
Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease
September 15th 2025
NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
Q&A: Strategies for Successful Global Clinical Trial Delivery
September 12th 2025
Trial Data Leads to NCCN Recommendation for Modeyso in Recurrent High Grade Glioma Patients
September 12th 2025

Trending on Applied Clinical Trials Online

Capvaxive Demonstrates Robust Immune Responses in Children, Adolescents at Increased Risk of Pneumococcal Disease

NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG

ACT Brief Weekly Recap: How AI, eClinical Innovation, and Policy Shifts Are Reshaping Clinical Research

Phase IV Trial Shows Daybue Demonstrates Real-World Behavioral Improvements in Rett Syndrome

© 2025 MJH Life Sciences^®

All rights reserved.